

## Summary of status of development and availability of A/Perth/16/2009(H3N2)-like\* candidate vaccine viruses\*\* and potency testing reagents

**31 May 2010**

### Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Perth/16/2009 (H3N2)	Wild type virus			WHO CCs NIBSC, UK
	NIB-64	Classical	NIBSC, UK	NIBSC, UK NIID, Japan
A/Hawaii/07/2009 (H3N2)	Wild type virus			WHO CCs
	CDCID-RG23	Reverse Genetics	CDC, USA	CDC, USA
A/Wisconsin/15/2009 (H3N2)	Wild type virus			WHO CCs NIBSC, UK
	NYMC X-183	Classical	New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
	CDCID-RG24	Reverse Genetics	CDC, USA	CDC, USA
A/Guangdong-Luohu/1256/2009 (H3N2)	Wild type virus			WHO CCs
	NYMC X-185	Classical	New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
	NYMC X-185xp			NYMC, USA NIID, Japan
A/Victoria/210/2009 (H3N2)	Wild type virus			WHO CCs NIBSC, UK
	IVR-155	Classical	CSL, Australia	NIBSC, UK NIID, Japan
	NYMC X-187		New York Medical College, USA	NYMC, USA NIBSC, UK NIID, Japan
NIB-65	NIBSC, UK		NIBSC, UK	
A/Hong Kong/26560/2009 (H3N2)	Wild type virus			WHO CCs
	NYMC X-189	Classical	New York Medical College, USA	NYMC, USA
A/Philippines/2191/2009 (H3N2)	Wild type virus			WHO CCs
	NYMC X-191	Classical	New York Medical College, USA	NYMC, USA

\* Antigenic and genetic analyses performed by the WHO Collaborating Centre for surveillance, epidemiology and control of influenza or by WHO Collaborating Centres for reference and research on influenza

\*\* National or Regional control authorities approve the composition and vaccines formulation used in each country ([http://www.who.int/immunization\\_standards/national\\_regulatory\\_authorities%20offices/en/](http://www.who.int/immunization_standards/national_regulatory_authorities%20offices/en/))

**Institutes contact details for candidate vaccine viruses orders/information:**

CDC: [rdonis@cdc.gov](mailto:rdonis@cdc.gov)  
 NIBSC: [standards@nibsc.hpa.org.uk](mailto:standards@nibsc.hpa.org.uk) or [enquiries@nibsc.hpa.org.uk](mailto:enquiries@nibsc.hpa.org.uk)  
 NIID: [sitamura@nih.go.jp](mailto:sitamura@nih.go.jp)  
 NYMC: [doris\\_bucher@nymc.edu](mailto:doris_bucher@nymc.edu)

**Reference antigens (freeze-dried)**

Parent virus	Starting materials		Ref Ag Lot #	Unitage (µgHA/mL)	Available from
	CVV	Egg or Cell			
A/Wisconsin/15/2009	NYMC X-183	Egg	2009/86B	75	TGA
			2010/87B	71	
			09/310	48	NIBSC
A/Victoria/210/2009	NYMC X-187		10/102	26	NIBSC
			70	71	CBER/FDA
			H3-Ag-1003	72	CBER/FDA

**Sheep antisera**

Purified HA from		Order / Lot #	Available from
Parent virus	Egg or Cell		
A/Perth/16/2009	Egg	09/270	NIBSC
A/Singapore/37/2009		AS400	TGA
A/Wisconsin/15/2009		H3-Ab-1005	CBER/FDA

The above-listed potency testing reagents for A/Perth/16/2009(H3N2)-like vaccines have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

**ERLs contact details for reagents orders/information:**

NIBSC: [standards@nibsc.hpa.org.uk](mailto:standards@nibsc.hpa.org.uk)  
 TGA: [influenza.standards@tga.gov.au](mailto:influenza.standards@tga.gov.au)

For general enquiries, please contact [GISN@who.int](mailto:GISN@who.int)

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/csr/disease/influenza/vaccinerecommendations2/en/index.html>